Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated With A Combination of Lapatinib and Capecitabine
-
Published:2023-04-01
Issue:2
Volume:19
Page:128-133
-
ISSN:2587-0831
-
Container-title:European Journal of Breast Health
-
language:
-
Short-container-title:EJBH
Author:
Doğan İzzetORCID, Paksoy NailORCID, Ak NaziyeORCID, Vatansever SezaiORCID, Saip PınarORCID, Aydıner AdnanORCID
Publisher
Galenos Yayinevi
Subject
Ocean Engineering
Reference21 articles.
1. 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71: 7-33. (PMID: 33433946) [Crossref] 2. 2. Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res 2015; 5: 2929-2943. (PMID: 26693050) [Crossref] 3. 3. Noone AM, Cronin KA, Altekruse SF, Howlader N, Lewis DR, Petkov VI, et al. Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992-2013. Cancer Epidemiol Biomarkers Prev 2017; 26: 632-641. (PMID: 27956436) [Crossref] 4. 4. Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int 2014; 2014: 852748. (PMID: 25276427) [Crossref] 5. 5. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533-543. (PMID: 18188694) [Crossref]
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|